Repurposed Drugs Slow Type 1 Diabetes Progression
- What: New research indicates antithymocyte globulin (ATG), verapamil, and baricitinib show promise in preserving beta cell function in individuals newly diagnosed with type 1 diabetes.
- Where: Clinical trials and ongoing research are primarily centered in academic medical centers globally.
- When: Data emerging as of September 2024, with potential for wider clinical submission in the coming years.
Hope for New-Onset Type 1 Diabetes: Emerging Therapies to Preserve Beta Cell Function
Table of Contents
Understanding Type 1 Diabetes and Beta Cell Loss
Type 1 diabetes is an autoimmune disease where the body’s immune system mistakenly attacks and destroys insulin-producing beta cells in the pancreas. This leads to a critical shortage of insulin, the hormone that regulates blood sugar. Traditionally, treatment has focused on managing blood glucose levels through exogenous insulin – injections or pump therapy.However, the goal of many researchers is to delay or even prevent the complete loss of beta cell function, offering the potential for a longer period of insulin independence.
The amount of functioning beta cells at the time of diagnosis is a strong predictor of long-term outcomes. The more beta cells remaining, the better the chances of maintaining some level of natural insulin production, which can improve blood sugar control and reduce the risk of complications.
the promise of antithymocyte Globulin (ATG)
Antithymocyte globulin (ATG) is an immunosuppressant medication already used to treat autoimmune diseases and prevent organ rejection after transplantation. Its mechanism involves depleting certain types of immune cells, theoretically reducing the autoimmune attack on beta cells. recent data suggest that early intervention with ATG in newly diagnosed type 1 diabetes patients can significantly slow the rate of beta cell decline.
While not a cure, ATG aims to reset
the immune system, giving remaining beta cells a chance to recover and function. It’s crucial to note that ATG carries risks, including potential side effects related to immunosuppression, requiring careful monitoring by a healthcare professional.
Verapamil: A repurposed Calcium Channel Blocker
Verapamil,a calcium channel blocker commonly used to treat high blood pressure and heart arrhythmias,has shown surprising potential in type 1 diabetes. Research indicates that verapamil may protect beta cells from autoimmune destruction by modulating calcium signaling within the cells. This can reduce the inflammatory response and preserve beta cell function.
the use of verapamil is particularly intriguing because it’s a relatively safe and inexpensive medication with a well-established safety profile.Though, the optimal dosage and duration of treatment are still being investigated.
Baricitinib: Targeting the Immune Pathway
Baricitinib is a Janus kinase (JAK) inhibitor, a class of drugs used to treat rheumatoid arthritis and other autoimmune conditions. It works by blocking specific signaling pathways involved in inflammation and immune cell activation. Studies suggest that baricitinib can dampen the autoimmune response in type 1 diabetes, potentially preserving beta cell function.
baricitinib has demonstrated promising results in clinical trials, showing a reduction in the rate of beta cell decline and improvements in insulin production. Like other immunosuppressants, it carries potential side effects that need to be carefully considered.
Putting it all Together: A Multi-Pronged Approach
The most exciting aspect of these findings is the potential for combining these therapies.Researchers are exploring whether using ATG, verapamil, and baricitinib in combination could provide a synergistic effect, maximizing beta cell preservation.This approach acknowledges the complex nature of type 1 diabetes and the need for a multi-faceted treatment strategy.
A hypothetical treatment timeline, starting at diagnosis, might involve initial ATG therapy to broadly suppress the immune system, followed by long-term verapamil and/or baricitinib to maintain immune modulation and protect beta cells